BECTON DICKINSON AND CO (NYSE:BDX) Reports Mixed Q3 2025 Earnings with Revenue Slightly Below Estimates but EPS Beat

BECTON DICKINSON AND CO (NYSE:BDX) reported its fiscal third-quarter 2025 earnings, delivering mixed results compared to analyst expectations. The medical technology giant posted revenue of $5.509 billion, marking a 10.4% year-over-year increase on a reported basis and 8.5% growth when adjusted for foreign exchange fluctuations. However, this figure fell slightly short of the consensus estimate of $5.541 billion.

On the earnings front, BDX outperformed expectations. Adjusted diluted earnings per share (EPS) came in at $3.68, surpassing the analyst forecast of $3.44. GAAP diluted EPS was $2.00, reflecting continued operational improvements despite macroeconomic pressures.

Market Reaction

The stock has shown modest pre-market gains of approximately 5.56%, suggesting investor optimism around the earnings beat. However, the stock has declined by 5.07% over the past two weeks, indicating some pre-earnings caution. The mixed revenue performance—slightly missing estimates while still showing solid growth—may explain the tempered but positive reaction.

Key Takeaways from the Earnings Release

• Revenue Growth: Strong reported growth of 10.4%, though slightly below expectations.
• EPS Strength: Adjusted EPS of $3.68 beat estimates, demonstrating margin resilience.
• Segment Performance: No detailed breakdown was provided in the press release, but BD’s diversified portfolio across medical devices, diagnostics, and life sciences likely contributed to stable performance.

Looking Ahead

Analysts expect BDX to generate full-year 2025 revenue of $22.043 billion, with Q4 sales projected at $5.958 billion. The company did not provide explicit guidance in the press release, leaving investors to rely on consensus estimates. The pre-market uptick suggests that the EPS beat is outweighing the slight revenue miss, but sustained momentum will depend on execution in the coming quarters.

For more detailed earnings estimates and historical performance, visit BDX Earnings & Estimates.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making any decisions.